For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 7,351,723 | 6,978,475.5* | 3,755,335 | 2,499,498 |
| General and administrative | 2,816,215 | 4,149,741* | 3,124,260 | 2,339,230 |
| Loss from operations | -10,167,938 | -11,128,216.5* | -6,879,595 | -4,838,728 |
| Interest income | 45 | 55.5* | 65 | 64 |
| Interest expense | 75,344 | - | - | 0 |
| Non-operating expenses | 153,594 | 368,248.75* | - | - |
| Change in fair value of warrant liability | - | 133,206.25* | - | -302,042 |
| Total other (expense) income | -228,893 | -501,399.5* | 65 | 302,106 |
| Net loss | -10,396,831 | -11,629,616 | -6,879,530 | -4,536,622 |
| Cumulative series a preferred stock dividend requirement | - | - | - | 0 |
| Net loss available to common shareholders | -10,396,831 | -11,629,616 | -6,879,530 | -4,536,622 |
| Basic EPS | -0.27 | -0.245* | -0.21 | -0.19 |
| Diluted EPS | -0.27 | -0.379 | -0.21 | -0.19 |
| Diluted Average Shares | 38,674,663 | 30,688,730 | 31,956,686 | 25,114,460 |
OS Therapies Inc (OSTX)
OS Therapies Inc (OSTX)